Indication
Targeting multiple major indications, including metastatic HR+/HER2- breast cancer, triple-negative breast cancer；
Non-small cell lung cancer, as well as various urological and gynecological tumors.
Product schedules
Entered Phase III clinical trials in China.
Molecular characteristics
Innovative highly-stable and cleavable linker, lysosomal protease-mediated toxin release；
Payload: SN38, a moderately active toxin with good tolerability；
Site-specific conjugation, DAR (8) is homogeneous and stable.
Much more better therapeutic response and progression-free survival compared to Trodelvy in HR+/HER2-BC
Outstanding efficacy data in 1L TNBC and the three breast cancer subtypes (TNBC, HR+/HER2-, and HER2+)
Rapid onset of action, long-lasting efficacy, effective against visceral metastasis (especially intracranial, liver, and lung metastasis), including patients who progressed after treatment with Transtuzumab deruxtecan (ENHERTU, DS-8201)
Compared to competitors, it offers advantages such as a higher maximum tolerated dose, a wider safety window, and greater flexibility for individualized dosing adjustments
An exceptional advantage in safety profile, with a low incidence of AEs and mild severity, supporting long-term treatment and combination therapy
